Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Genentech is teaming up with Bicycle Therapeutics to develop cancer immunotherapies. Bicycle uses chemical scaffolds to turn linear peptides into two pretzel-like loops. The firm says these so-called bicyclic peptides can be used as drugs alone or to deliver toxic payloads to cancer cells. Bicycle has several cancer drug programs of its own. Genentech will pay Bicycle $30 million up front—and up to $1.7 billion in milestone payments—to develop bicyclic peptides against several new targets.
This article has been sent to the following recipient: